Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway

Cell Cycle

Volumn 13, Issue 18, 2014, Pages 2962-2974

  Lv, Hongjun ^a   Liu, Rui ^a   Fu, Jiao ^a   Yang, Qi ^a   Shi, Jing ^a   Chen, Pu ^a   Ji, Meiju ^a   Shi, Bingyin ^a   Hou, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

E cadherin; Gastric cancer; Mdm2; P53; Periostin; Rb E2F1 pathway

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR RUNX2; UVOMORULIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; ENZYME INACTIVATION; EPITHELIUM CELL; GASTRIC CANCER CELL LINE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LYMPH NODE METASTASIS; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; STOMACH CANCER; STOMACH MUCOSA; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

EID: 84908192390     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.947203     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
2. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013; 11:531-46; PMID:23667204
3. Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers 2013; 5:48-63; PMID:24216698; http://dx.doi.org/10.3390/cancers5010048
4. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer-slow but steady progress. Cancer Treat Rev 2010; 36:384-92; PMID:20176443; http://dx.doi.org/10.1016/j.ctrv.2010.01.005
5. Wong GS, Rustgi AK. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer 2013; 108:755-61; PMID:23322204; http://dx.doi.org/10.1038/bjc.2012.592
6. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4:839-49; PMID:15516957; http://dx.doi.org/10.1038/nrc1477
7. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 2009; 66:2219-30; PMID:19308325; http://dx.doi.org/10.1007/s00018-009-0013-7
8. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004; 5:329-39; PMID:15093540; http://dx.doi.org/10.1016/S1535-6108(04)00081-9
9. Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim SB, Herlyn M, et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res 2010; 70:5281-92; PMID:20516120; http://dx.doi.org/10.1158/0008-5472.CAN-10-0704
10. Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T, Lemoine NR. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 2007; 26:2082-94; PMID:17043657; http://dx.doi.org/10.1038/sj. onc.1210009
11. Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D'Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G, et al. Expression of periostin in human breast cancer. J Clin Pathol 2008; 61:494-8; PMID:17938160; http://dx.doi.org/10.1136/jcp. 2007.052506
12. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 2008; 14:7430-7; PMID:19010860; http://dx.doi.org/10.1158/1078-0432.CCR-08-0935
13. Choi KU, Yun JS, Lee IH, Heo SC, Shin SH, Jeon ES, Choi YJ, Suh DS, Yoon MS, Kim JH. Lysophosphatidic acid-induced expression of periostin in stromal cells: prognoistic relevance of periostin expression in epithelial ovarian cancer. Int J Cancer 2011; 128:332-42; PMID:20309942; http://dx.doi.org/10.1002/ijc.25341
14. Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezavi A, Gerhardt J, Schraml P, et al. Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer 2010; 10:273; PMID:20534149; http://dx.doi.org/10.1186/1471-2407-10-273
15. Kim CJ, Yoshioka N, Tambe Y, Kushima R, Okada Y, Inoue H. Periostin is down-regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells. Int J Cancer 2005; 117:51-8; PMID:15880581; http://dx.doi.org/10.1002/ijc.21120
16. Kikuchi Y, Kunita A, Iwata C, Komura D, Nishiyama T, Shimazu K, Takeshita K, Shibahara J, Kii I, Morishita Y, et al. The niche component periostin is produced by cancer-associated fibroblasts, supporting growth of gastric cancer through ERK activation. Am J Pathol 2014; 184:859-70; PMID:24418260; http://dx.doi.org/10.1016/j.ajpath.2013.11.012
17. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74; PMID:11990853; http://dx.doi.org/10.1038/nrc745
18. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9:738-48; PMID:19776743; http://dx.doi.org/10.1038/nrc2718
19. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68:3645-54; PMID: 18483246; http://dx.doi.org/10.1158/0008-5472. CAN-07-2938
20. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z, Broglio K, Berry DA, Hung MC. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol 2006; 26:7269-82; PMID:16980628; http://dx.doi.org/10.1128/MCB. 00172-06
21. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98:11598-603; PMID:11504915; http://dx.doi.org/10.1073/pnas.181181198
22. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I, Haigis K, Gulino A, Lees JA. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009; 15:184-94; PMID:19249677; http://dx.doi.org/10.1016/j.ccr.2009.01.026
23. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH. p14ARF links the tumour suppressors RB and pNature 1998; 395:124-5; PMID:9744267; http://dx.doi.org/10.1038/25867
24. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34; PMID:9529249; http://dx.doi.org/10.1016/S0092-8674(00)81401-4
25. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p. Cell 1998; 92:713-23; PMID:9529248; http://dx.doi.org/10.1016/S0092-8674(00)81400-2
26. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998; 95:8292-7; PMID:9653180; http://dx.doi.org/10.1073/pnas.95. 14.8292
27. Aoki I, HiguchiM, Gotoh Y. NEDDylation controls the target specificity of E2F1 and apoptosis induction. Oncogene 2013; 32:3954-64; PMID:23001041; http://dx.doi.org/10.1038/onc.2012.428
28. Wong GS, Lee JS, Park YY, Klein-Szanto AJ, Waldron TJ, Cukierman E, HerlynM, Gimotty P, Nakagawa H, Rustgi AK. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment. Oncogenesis 2013; 2:e59; PMID:23917221; http://dx.doi.org/10.1038/oncsis.2013.17
29. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13:97-110; PMID:23344542; http://dx.doi.org/10.1038/nrc3447
30. Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterologie 2005; 43:1133-9; PMID:16220453; http://dx.doi.org/10.1055/s-2005-858638
31. Utispan K, Sonongbua J, Thuwajit P, Chau-In S, Pairojkul C, Wongkham S, Thuwajit C. Periostin activates integrin alpha5beta1 through a PI3K/AKTdependent pathway in invasion of cholangiocarcinoma. Int J Oncol 2012; 41:1110-8; PMID: 22735632; http://dx.doi.org/10.3892/ijo.2012.1530
32. Kim CJ, Sakamoto K, Tambe Y, Inoue H. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells. Int J Oncol 2011; 38:1759-66; PMID:21468544; http://dx.doi.org/10.3892/ijo.2011.997
33. Ouyang GL, Liu M, Ruan K, Song G, Mao YB, Bao SD. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett 2009; 281:213-9; PMID:19328625; http://dx.doi.org/10.1016/j.canlet.2009.02.030
34. Kanno A, Satoh K, Masamune A, Hirota M, Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, et al. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer 2008; 122:2707-18; PMID:18381746; http://dx.doi.org/10.1002/ijc.23332
35. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8:671-82; PMID:18650841; http://dx.doi.org/10.1038/nrc2399
36. Julian LM, Palander O, Seifried LA, Foster JE, Dick FA. Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation. Oncogene 2008; 27:1572-79; PMID:17891180; http://dx.doi.org/10.1038/sj.onc.1210803
37. Ma D, Zhou P, Harbour JW. Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. J Biol Chem 2003; 278:19358-66; PMID:12646568; http://dx.doi.org/10.1074/jbc. M301761200
38. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008; 13:11-22; PMID:18167336; http://dx.doi.org/10.1016/j.ccr.2007.11.031
39. Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A 2003; 100:10848-53; PMID:12954980; http://dx.doi.org/10.1073/pnas.1831408100
40. Hang X, Li P, Li Z, Qu W, Yu Y, Li H, Shen Z, Zheng H, Gao Y, Wu Y, et al. Transcription and splicing regulation in human umbilical vein endothelial cells under hypoxic stress conditions by exon array.BMCgenomic 2009; 10:126; PMID:19320972; http://dx.doi.org/10.1186/1471-2164-10-126
41. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006; 1:241-5; PMID:17406239; http://dx.doi.org/10.1038/nprot.2006.37
42. Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, et al. TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). Clin Cancer Res 2012; 18:4201-12; PMID:22675170; http://dx.doi.org/10.1158/1078-0432.CCR-12-0036